Heterocyclic Compound Is Attached To Or Complexed With The Metal Patents (Class 424/9.361)
  • Patent number: 10716861
    Abstract: A composition in the form of a water-in-oil emulsion comprising: from 20% to 40% (v/v) of aqueous phase, in the form of droplets, comprising an anti-cancer agent and a densifying agent chosen from the complexes of nonionic macrocyclic chelate with a paramagnetic metal, from 60% to 80% (v/v) of lipid phase comprising an iodized oil and at least one surfactant of formula (I) in a proportion, by weight of surfactant relative to the total volume of the composition, of 0.3% to 5%, formula (I) of said surfactant being the following: in which: s is 0 or 1, m is an integer from 2 to 30, R1 represents a group of formula (II) in which n is an integer from 4 to 10, o is an integer from 1 to 4, p is an integer from 3 to 7, q is an integer from 2 to 10, and r is 0 or 1, R2 represents a hydrogen atom or is identical to R1, and each R3 independently represents a hydrogen atom or is identical to R1.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: July 21, 2020
    Assignee: GUERBET
    Inventors: Caroline Robic, Jean-François Mayer
  • Patent number: 10478120
    Abstract: The present invention provides a method of administering a therapeutic agent directly to the brain parenchym through a compromised region of the blood-brain barrier in a subject having a brain disorder, that involves first disrupting the blood-brain barrier (BBB) at an isolated region by locally administering an effective amount of a hyperosmolar agent at said region using a catheter, followed by administering a therapeutically effective amount of a therapeutic agent. The step of disrupting the BBB is carried out with non-invasive MR (magnetic resonance) imaging with a contrast agent to visualize local parenchymal transcatheter perfusion at said isolated BBB region thereby indicating that the BBB region is compromised. The method of the invention allows for highly precise drug delivery to the brain through blood brain barrier disruption at specifically controlled regions.
    Type: Grant
    Filed: May 17, 2015
    Date of Patent: November 19, 2019
    Assignee: The Johns Hopkins University
    Inventors: Piotr Walczak, Monica Pearl, Miroslaw Janowski
  • Patent number: 10234527
    Abstract: For the purpose of obtaining a spectrum suitable for acquiring information on a CEST effect, an MR apparatus comprises a Z-spectrum generating unit 91 for generating a Z-spectrum containing a CEST component representing a signal component affected by CEST and a baseline component representing a signal component unaffected by CEST based on data acquired by a plurality of sequences; a spectrum transforming unit 92 for transforming the Z-spectrum into a CPE spectrum; and first fitting unit 95 for calculating values of a plurality of coefficients included in a CEST term in an approximate expression of the CPE spectrum.
    Type: Grant
    Filed: May 11, 2016
    Date of Patent: March 19, 2019
    Assignee: GENERAL ELECTRIC COMPANY
    Inventor: Mitsuharu Miyoshi
  • Patent number: 9732047
    Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.
    Type: Grant
    Filed: December 21, 2015
    Date of Patent: August 15, 2017
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Richard R. Cesati, Thomas D. Harris, Richard J. Looby, Edward H. Cheesman, David S. Casebier
  • Patent number: 9266846
    Abstract: The present disclosure is directed to compounds, diagnostic agents, and related methods. In some cases, methods for treating patients are provided. More specifically, the disclosure provides compounds, diagnostic agents, and kits for detecting and/or imaging and/or monitoring elastin rich tissues. In addition, the disclosure provides methods of detecting and/or imaging and/or monitoring the presence of coronary plaque, carotid plaque, iliac/femoral plaque, aortic plaque, renal artery plaque, plaque of any arterial vessel, aneurism, vasculitis, other diseases of the arterial wall, and/or damage or structural changes in ligaments, uterus, lungs or skin, as indicated by changes in total vessel wall area, internal lumen size, and exterior arterial perimeter.
    Type: Grant
    Filed: September 2, 2014
    Date of Patent: February 23, 2016
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Richard R. Cesati, Thomas D. Harris, Simon P. Robinson, Richard J. Looby, Edward H. Cheesman, Padmaja Yalamanchili, David S. Casebier
  • Patent number: 9259491
    Abstract: The present invention relates to a new class of diazepine-derivatives as chelating agents for paramagnetic metal ions, the process for their preparation, and use of such paramagnetic complexes as contrast agents, particularly suitable for Magnetic Resonance Imaging (MRI) analysis. The present invention refers to a new class of derivatives of formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: February 16, 2016
    Assignee: Bracco Imaging S.P.A.
    Inventors: Lorena Beltrami, Luciano Lattuada, Alessandro Maiocchi, Massimo Visigalli, Loredana Sini
  • Patent number: 9034298
    Abstract: Described are amphiphilic polymers that are provided with chelating moieties. The amphiphilic polymers are block copolymers comprising a hydrophilic block and a hydrophobic block, with the chelating moieties linked to the end-group of the hydrophilic block. The disclosed polymers are capable of self-assembly into structures such as micelles and polymersomes. With suitable metals present in the form of coordination complexes with 5 the chelating moieties, the chelating amphiphilic polymers of the invention are suitable for use in various imaging techniques requiring metal labeling, such as MRI (T 1/T 2 weighted contrast agents or CEST contrast agents) SPECT, PET or Spectral CT.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: May 19, 2015
    Assignee: Koninklijke Philips N.V.
    Inventors: Holger Gruell, Anke De Vries, Sander Langereis, Johan Lub, Erica M. G. Aussems-Custers
  • Publication number: 20150037253
    Abstract: The present invention relates to copper, gallium and technetium coordinated thiosemicarbazone-pyridylhydrazine (substituted at the pyridine ring with a substituted benzothiazole or stilbene moiety) complexes and methods thereof. Such compounds possess utility in PET imaging and diagnosis of amyloid diseases.
    Type: Application
    Filed: December 6, 2012
    Publication date: February 5, 2015
    Inventors: Paul Donnelly, James Hickey, Kevin Barnham, Sin Chun Lim
  • Publication number: 20150037261
    Abstract: The present invention relates to a new class of diazepine-derivatives as chelating agents for paramagnetic metal ions, the process for their preparation, and use of such paramagnetic complexes as contrast agents, particularly suitable for Magnetic Resonance Imaging (MRI) analysis.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 5, 2015
    Applicant: BRACCO IMAGING S.P.A.
    Inventors: Lorena Beltrami, Luciano Lattuada, Alessandro Maiocchi, Massimo Visigalli, Loredana Sini
  • Patent number: 8815213
    Abstract: RGD-chlorophyll and RGD-bacteriochlorophyll conjugates that home and accumulate in necrotic tumor domains much longer than in tumor non-necrotic domains are provided for use in minimally invasive tumor-targeted imaging, tumor-targeted photodynamic therapy, and/or on-line prognosis of necrotic tumors.
    Type: Grant
    Filed: March 1, 2009
    Date of Patent: August 26, 2014
    Assignee: Yeda Research and Development Co. Ltd.
    Inventors: Avigdor Scherz, Liat Goldshaid, Yoram Salomon
  • Patent number: 8758726
    Abstract: The present application discloses compositions and methods of synthesis and use of 18F or 19F-labeled molecules of use in PET, SPECT and/or MR imaging. Preferably, the 18F or 19F is conjugated to a targeting molecule by formation of a complex with a group IIIA metal and binding of the complex to a bifunctional chelating agent, which may be directly or indirectly attached to the targeting molecule. In other embodiments, the 18F or 19F labeled moiety may comprise a targetable construct used in combination with a bispecific antibody to target a disease-associated antigen. The disclosed methods and compositions allow the simple and reproducible labeling of molecules at very high efficiency and specific activity in 30 minutes or less. In preferred embodiments, the labeled molecule may be used for imaging in a subject without purification after labeling.
    Type: Grant
    Filed: August 28, 2013
    Date of Patent: June 24, 2014
    Assignee: Immunomedics, Inc.
    Inventors: Christopher A. D'Souza, William J. McBride, David M. Goldenberg
  • Publication number: 20140072517
    Abstract: Compounds and uses of the compounds are provided. The compounds can be used as Fe(II) sequestering compounds. For example, these compounds can be used to sequester Fe(II) in cells, organs, vasculature, or tissues. Also, provided are compositions and methods of using the them for sequestering Fe(II) in an individual. The compounds can be used as MRI paraCEST contrast agents.
    Type: Application
    Filed: May 11, 2012
    Publication date: March 13, 2014
    Applicant: The Research Foundation of State University of New
    Inventors: Janet Morrow, Pavel Tsitovich
  • Publication number: 20130302257
    Abstract: The present invention provides compositions and methods for the delivery of nucleic acids to a cell. The present invention additionally provides compositions and methods for the treatment of a disease or disorder, particularly cancer.
    Type: Application
    Filed: August 17, 2011
    Publication date: November 14, 2013
    Applicants: UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY, RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY
    Inventors: Tamara Minko, Lorna Rodriguez-Rodriguez, Olga B. Garbuzenko, Oleh Taratula, Vatsal Shah
  • Patent number: 8562953
    Abstract: A dendritic polymer and a magnetic resonance imaging contrast agent employing the same. The magnetic resonance contrast agent includes the dendritic polymer according to the structure of SP-DZ-L)i)j or SP-DX-Z-L)i)j, wherein, S is cyclosilane moiety with j silicon oxygen residual groups, and j is not less than 2; P is CH2CH2Ol, and l is not less than 1; D is a C3-30 dendritic moiety having n oxygen residue, and n is not less than 3; X is C3-30 moiety having bi-functional groups; Z is a C3-20 moiety having a plurality of functional group; and L is a metal cation.
    Type: Grant
    Filed: October 2, 2012
    Date of Patent: October 22, 2013
    Assignee: Industrial Technology Research Institute
    Inventors: Dhakshanamurthy Thirumalai, Chin-I Lin, Shian-Jy Wang
  • Patent number: 8454935
    Abstract: A cell permeable probe is disclosed. The cell permeable probe includes a cell membrane translocating element, which facilitates transport of the probe into the intracellular component of a cell. The cell permeable probe may also include a plurality of binding moieties for a disease specific marker and a contrast agent.
    Type: Grant
    Filed: July 12, 2007
    Date of Patent: June 4, 2013
    Assignee: Case Western Reserve University
    Inventors: James P. Basilion, Jihua Hao
  • Patent number: 8414866
    Abstract: The present invention relates to a magnetic resonance imaging (MRI) method, in particular to a MRI method enabling early detection of myocardial ischemia.
    Type: Grant
    Filed: December 16, 2008
    Date of Patent: April 9, 2013
    Assignee: GE Healthcare AS
    Inventors: Morten Eriksen, Geir Torheim
  • Patent number: 8404216
    Abstract: The invention relates to dendritic chelated compounds, to methods for producing the same and to pharmaceutical compositions containing the same. The dendritic chelated complexes of the present invention have the following formula (I): [[MC]En-[D]m-X1p1X2p2X3p3X4p4]z?zB+ (I), where m is a magnetic or scintigraphic marker, C is a chelating agent of the marker M, E is a spacer, n=0 or 1, D is compound capable of forming a dendritic structure, m is an integer equal to 1 or 2 or 4, X1 is a group increasing the complex lipophily, p1 is an integer from 0 to 12, X2 is a group increasing the complex specificity for a particular organ, p2 is an integer equal to 1 or 2 or 4, X3 is a group having a therapeutic activity, p3 is an integer equal to 0, 1, 2 or 4, X4 is a CH3 group, p4 is an integer from 0 to 12, B is a counter-ion, z is an integer equal to 0, 1, 2, 3 or 4. The invention can be used in the field of pharmacy, more precisely in medical imaging.
    Type: Grant
    Filed: October 9, 2007
    Date of Patent: March 26, 2013
    Assignees: Centre National de la Recherche Scientifique, Universite Louis Pasteur
    Inventors: Delphine Felder-Flesch, Jérôme Steibel, Annabelle Bertin
  • Patent number: 8361494
    Abstract: An engineered lipoprotein including (a) a core particle or a plurality of core particles, each core particle has (i) an inner part comprising a hydrophilic active agent and a hydrophilic portion of an amphiphilic cholesterol and (ii) an outer part including a hydrophobic portion of the amphiphilic cholesterol, (b) a layer surrounding the core particle or a plurality of core particles, the layer includes a phospholipid, (c) an apoprotein associated with the layer, and optionally, (d) a homing molecule associated with at least one of the apoprotein or the phospholipid.
    Type: Grant
    Filed: March 6, 2007
    Date of Patent: January 29, 2013
    Assignee: The Trustees Of The University of Pennsylvania
    Inventors: I-Wei Chen, Hoon Choi
  • Patent number: 8323621
    Abstract: Cyclen-based chelates can be used as contrast agents for multi-modal imaging of tissue cells. The cyclen-based chelates are preferably polyazamacrocyclic molecules formed from 1,4,7,10 tetraazacyclododecane (“cyclen”) having varying chelating ions, phosphoester chains, and light harvesting moieties. By changing the chelating ion, phosphoester chain length and/or the light harvesting moiety different imaging techniques, such as MRI, CT, fluorescence and absorption, x-ray and NIR, may be employed to image the tissue cells. Additionally, the cyclen-based chelates may be conjugated to provide for site-specific delivery of the cyclen-based chelate to the desired tissue cells. The cyclen-based chelates may also be delivered to the tissue cells by attaching the cyclen-based to a polymeric delivery vehicle. Although these cyclen-based chelates have a wide variety of application, the preferred use is for imaging of cancer cells, such as brain cancer, for improving resection of a cancerous tissue.
    Type: Grant
    Filed: March 4, 2008
    Date of Patent: December 4, 2012
    Assignees: Vanderbilt University, Texas Tech University System
    Inventors: Darryl J. Bornhop, H. Charles Manning, Timothy Goebel
  • Patent number: 8303937
    Abstract: A dendritic polymer and a magnetic resonance imaging contrast agent employing the same. The magnetic resonance contrast agent includes the dendritic polymer according to the structure of SP-DZ-L)i)j or SP-DX-Z-L)i)j, wherein, S is cyclosilane moiety with j silicon oxygen residual groups, and j is not less than 2; P is and l is not less than 1; D is a C3-30 dendritic moiety having n oxygen residue, and n is not less than 3; X is C3-30 moiety having bi-functional groups; Z is a C3-20 moiety having a plurality of functional group; and L is a metal cation.
    Type: Grant
    Filed: July 16, 2008
    Date of Patent: November 6, 2012
    Assignee: Industrial Technology Research Institute
    Inventors: Dhakshanamurthy Thirumalai, Chin-I Lin, Shian-Jy Wang
  • Publication number: 20120276006
    Abstract: The present disclosure is directed, in part, to compounds and methods for imaging myocardial perfusion, comprising administering to a patient a contrast agent which comprises a compound that binds MC-1, and an imaging moiety, and scanning the patient using diagnostic imaging.
    Type: Application
    Filed: June 21, 2012
    Publication date: November 1, 2012
    Applicant: Lantheus Medical Imaging, Inc.
    Inventors: David S. Casebier, Simon P. Robinson, Ajay Purohit, Heike S. Radeke, Michael T. Azure, Douglas D. Dischino
  • Patent number: 8299285
    Abstract: A metal complex of formula (III) wherein: M is a transition metal and A1, A2, X, X?, Y, L1?, R1? and R2? are as defined herein, is useful in medical imaging and therapy.
    Type: Grant
    Filed: July 5, 2006
    Date of Patent: October 30, 2012
    Assignee: Isis Innovation Limited
    Inventors: Jonathan Robin Dilworth, Josephine Mary Peach, Julia May Heslop, Paul Stephen Donnelly
  • Publication number: 20120269738
    Abstract: The present invention relates to methods of detecting and monitoring aggregation of beta-amyloid peptides which are associated with neurodegenerative diseases as well as treating and/or preventing the neurodegenerative diseases by using carbazole-based fluorophores. In particular, the present invention provides methods for labeling and imaging the beta-amyloid (A?) peptides, oligomers, and fibrils in vitro and/or in vivo, as well as treating and/or preventing Alzheimer's disease by using the carbazole-based fluorophores of the present invention.
    Type: Application
    Filed: April 13, 2012
    Publication date: October 25, 2012
    Applicant: Hong Kong Baptist University
    Inventors: Wanggui YANG, Yi WONG, Olivia T. W. NG, Hung Wing LI, Ken K. L. YUNG, Daniel W. J. KWONG, Ricky M. S. WONG
  • Publication number: 20120213702
    Abstract: The present invention relates to aminopeptidase N (APN) inhibitor conjugates of formula I wherein W is a —CO— or an —SO2— group and at least one of R1 or R2 represents (OCH2—CH2)n-X, where n is an integer of 1 to 100 and X represents H or a detectable label or a therapeutic, and the other represents an alkoxy group or OH, and wherein R3, R3? and R3? is independently selected from an alkoxy group or (OCH2—CH2)n-X, where n is an integer of 1 to 100 and X represents H or a detectable label or a therapeutic, and R4 is selected from the group comprising: wherein R is an alkyl group. Furthermore, the present invention relates to a diagnostic and/or pharmaceutical composition comprising the conjugate of the invention.
    Type: Application
    Filed: August 31, 2010
    Publication date: August 23, 2012
    Inventors: Christoph Bremer, Carsten Höltke
  • Publication number: 20120121509
    Abstract: The present invention provides compositions and methods based on vital fluorochrome conjugates that are useful for imaging dying and dead cells.
    Type: Application
    Filed: June 4, 2010
    Publication date: May 17, 2012
    Applicant: THE GENERAL HOSPITAL CORPORATION
    Inventors: Lee Josephson, Elisabeth Garanger, Scott Hilderbrand, David Sosnovik, Hushan Yuan
  • Patent number: 8173106
    Abstract: The invention relates to a method of co-administering a peptide or protein drug with an enzyme-resistant PGA-complexone compound orally so to mitigate enzyme attack in the gastrointestinal tract of an animal subject.
    Type: Grant
    Filed: December 13, 2011
    Date of Patent: May 8, 2012
    Assignees: GP Medical, Inc., National Tsing Hua University
    Inventors: Hsing-Wen Sung, Kiran Sonaje, Hosheng Tu
  • Publication number: 20110274626
    Abstract: There is described a method of selective observation of non-hydrogenative para-hydrogen induced polarisation (NH-PHIP) as enhanced magnetic resonance signals which comprises separating the thermal and longitudinal spin order states. There is also described a template comprising [Ir(COD)(NHC)(Py)]+, and analogues thereof, for use in a PHIP magnetic resonance technique and a method for its preparation.
    Type: Application
    Filed: December 10, 2009
    Publication date: November 10, 2011
    Applicant: UNIVERSITY OF YORK
    Inventors: Simon Benedict Duckett, Gary George Reginald Green, Michael James Cowley
  • Publication number: 20110243859
    Abstract: The present invention relates to the use of a CEST contrast agent in a method of CEST imaging, wherein the contrast agent is a composition comprising an encapsulating system ES encapsulating at least one CEST agent, wherein the at least one CEST agent is constituted of a monomeric chelate of a chelate of q?2 type, or of a multimer of monomeric chelates of q?2 type, and wherein said chelate is free inside the encapsulating system.
    Type: Application
    Filed: December 9, 2009
    Publication date: October 6, 2011
    Applicant: GUERBET
    Inventor: Marc Port
  • Patent number: 8017105
    Abstract: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical compositions comprising these compounds and to methods of using the compounds and compositions for blood half-life extension and contrast enhancement of diagnostic imaging.
    Type: Grant
    Filed: June 22, 2006
    Date of Patent: September 13, 2011
    Assignee: Lantheus Medical Imaging, Inc.
    Inventors: Thomas J. McMurry, Hironao Sijiki, Daniel M. Scott, Randall B. Lauffer
  • Patent number: 8012458
    Abstract: The invention is directed to a lanthamide chelate composition having a lanthamide, a charged amidate ligand, and a mono- or bidentate neutrally charged coordination compound, the composition being represented by structure I or structure II wherein Ln3+ designates lanthamide, R1 is alkyl, aryl, or heteroaryl; R2 is alkyl, aminoalkyl, aryl or heteroaryl; M is a neutrally charged monodentate coordination compound, M? is a neutrally charged bidentate coordination compound, a=1 or 2; and wherein M and M? comprise N, S, or O. It extends to the process of making the composition.
    Type: Grant
    Filed: June 8, 2007
    Date of Patent: September 6, 2011
    Assignee: E. I. du Pont de Nemours and Company
    Inventor: Damien F. Reardon
  • Patent number: 8003078
    Abstract: MRI contrast agents that employ paramagnetic agents and chemical exchange saturation transfer (paraCEST) and which are coupled to targeted particulate delivery vehicles provide sufficient concentration of the paraCEST contrast agents to obtain useful images of target tissues or organs. In addition, the image contrast may be switched on or off with a presaturation radio frequency pulse, avoiding the necessity obtaining pre-injection and post-injection images.
    Type: Grant
    Filed: March 29, 2007
    Date of Patent: August 23, 2011
    Assignee: Barnes-Jewish Hospital
    Inventors: Gregory M. Lanza, Samuel A. Wickline, Garry E. Kiefer, Phillip S. Athey
  • Publication number: 20110200536
    Abstract: The present invention relates to chelators, in particular to chelators which are capable of forming complexes, i.e. paramagnetic chelates, with paramagnetic metal ions. The invention also relates to said paramagnetic chelates, said paramagnetic chelates linked to other molecules and their use as contrast agents in magnetic resonance imaging (MRI).
    Type: Application
    Filed: August 12, 2008
    Publication date: August 18, 2011
    Inventors: Harry John Wadsworth, Ian Martin Newington, Dennis O'shea
  • Patent number: 7917188
    Abstract: A method for mapping a physico-chemical parameter using a chemical exchange saturation transfer contrast agent in Magnetic Resonance Imaging is used with agents having only one exchangeable entity pool, e.g. proton pool, by applying two different RF frequencies for pre-saturation of the contrast agent.
    Type: Grant
    Filed: April 21, 2006
    Date of Patent: March 29, 2011
    Assignee: Koninklijke Philips Electronics N.V.
    Inventors: Rene Theodorus Wegh, Jeroen Alphons Pikkemaat, Nicolaas Petrus Willard
  • Patent number: 7897140
    Abstract: Novel tetrapyrollic water soluble photosensitizing and imaging compounds and the methods of treating and imaging hyperproliferative tissue, e.g. tumors and hypervacularized tissue such as found in macular degeneration. Broadly, the compounds are tetrapyrollic photosensitizer compounds where the tetrapyrollic compound is a chlorin, bacteriochlorin, porphyrin, pyropheophorbide, purpurinimide, or bacteriopurpurinimide having 3 to 6 —CH2CONHphenylCH2CH(N(CH2COOH)2))(CH2N(CH2COOH)(CH2CH2N(CH2COOH)2)) groups or esters thereof or complexes thereof with gadolinium(III).
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: March 1, 2011
    Assignee: Health Research, Inc.
    Inventors: Ravindra K. Pandey, Lalit Goswami, Joseph Spernyak, Peter Kanter, Richard Mazurchuk
  • Patent number: 7727512
    Abstract: Compounds useful for associating with nanoparticle or microparticle emulsions to obtain magnetic resonance images permit control of the relaxivity of the signal and readily associate with the particulate components.
    Type: Grant
    Filed: October 9, 2007
    Date of Patent: June 1, 2010
    Assignees: Barnes-Jewish Hospital, The Dow Chemical Company
    Inventors: Gregory M. Lanza, Samuel A. Wickline, Phillip S. Athey, Gyongyi Gulyas, Garry E. Kiefer
  • Publication number: 20100098640
    Abstract: Provided herein are chelating agents and metal chelates that are useful in diagnostic and therapeutic applications. The uses of metal chelates provided herein include their use as contrast agents in medical imaging modalities, such as magnetic resonance imaging (MRI).
    Type: Application
    Filed: June 20, 2006
    Publication date: April 22, 2010
    Inventors: Seth M. Cohen, David T. Puerta
  • Publication number: 20100008864
    Abstract: The present invention relates to novel compounds of formula (I) and (II), compositions comprising compounds of formula (II) and their use as contrast agents in magnetic resonance (MR) imaging (MRI) and MR spectroscopy (MRS).
    Type: Application
    Filed: July 8, 2009
    Publication date: January 14, 2010
    Inventors: Andreas Meijer, Harry John Wadsworth, Ian Martin Newington, Clare L. Jones, Amanda Ewan, Dennis O'Shea, Oskar Axelsson, Anders Brathe, Andreas Olsson, John Henrik Johansen, Duncan George Wynn
  • Patent number: 7608249
    Abstract: The invention relates to a method for the Magnetic Resonance Imaging and Magnetic Resonance Spectroscopy Imaging of a substrate molecule different from water wherein the NMR signal is enhanced by a reversible binding of the substrate molecule to a paramagnetic chelate complex, as well as to the use of a paramagnetic chelate complex in said method and the pharmaceutical composition for use therein.
    Type: Grant
    Filed: October 9, 2002
    Date of Patent: October 27, 2009
    Assignee: Bracco Imaging S.p.A.
    Inventors: Enzo Terreno, Silvio Aime, Mauro Botta
  • Publication number: 20090263332
    Abstract: A magnetic resonance imaging agent which includes: a polymer containing the structural unit represented by the following formula (I) and the structural unit represented by the following formula (II) in a molar ratio of 5 to 80:20 to 95; a paramagnetic metal compound; and a ligand molecule: wherein R1 represents hydrogen atom or methyl group; R2 represents a hydrogen atom or a methyl group; A represents —(CH2)2N+(CH3)3 or the like; and B represents oxygen atom, sulfur atom, —CH2—, or —NH—; and R4 represents hydrogen atom, an optionally substituted alkyl group, or an optionally substituted aryl group, which affords good retention in the blood and a good ability to accumulate in diseased areas.
    Type: Application
    Filed: April 20, 2009
    Publication date: October 22, 2009
    Applicant: FUJIFILM CORPORATION
    Inventors: Takashi TAMURA, Kazuya TAKEUCHI, Kazuhiro AIKAWA
  • Publication number: 20090246145
    Abstract: This invention provides a method for treating a mammalian subject afflicted with a disorder associated with reduced neurogenesis in the subject's hippocampal dentate gyrus which comprises administering to the subject a therapeutically effective amount of a compound which increases cerebral blood volume in the subject's hippocampal dentate gyrus by a percentage greater than that by which it increases the cerebral blood volume in the subject's hippocampal CA1 region, thereby treating the subject.
    Type: Application
    Filed: November 14, 2006
    Publication date: October 1, 2009
    Inventor: Scott A. Small
  • Publication number: 20090238768
    Abstract: The present invention relates to novel compounds of formula (I) and (II), compositions comprising compounds of formula (II) and their use as contrast agents in magnetic resonance (MR) imaging (MRI) and MR spectroscopy (MRS).
    Type: Application
    Filed: December 1, 2006
    Publication date: September 24, 2009
    Inventors: Oskar Axelsson, Haukur Johannesson, Andreas Meijer, Andreas Olsson, Tim Stahlberg, Mikkel Thaning, Duncan Wynn, Anders Brathe
  • Publication number: 20090208421
    Abstract: The invention relates to a process for preparing a liquid pharmaceutical formulation containing a complex of macrocyclic chelate with a lanthanide and a mol/mol amount of free macrocyclic chelate of between 0.002% and 0.4%, advantageously between 0.02% and 0.3% and very advantageously between 0.025% and 0.
    Type: Application
    Filed: June 12, 2008
    Publication date: August 20, 2009
    Inventors: Dominique Meyer, Claire Corot
  • Publication number: 20090155184
    Abstract: The present invention relates to a magnetic resonance imaging (MRI) method, in particular to a MRI method enabling early detection of myocardial ischemia.
    Type: Application
    Filed: December 16, 2008
    Publication date: June 18, 2009
    Applicant: GE HEALTHCARE AS
    Inventors: Morten Eriksen, Geir Torheim
  • Publication number: 20090004119
    Abstract: The present invention relates to novel linear polymers, compositions comprising said polymers and their use as contrast agents in magnetic resonance (MR) imaging (MRI) and magnetic resonance spectroscopy (MRS).
    Type: Application
    Filed: June 26, 2008
    Publication date: January 1, 2009
    Applicant: GE HEALTHCARE AS
    Inventors: Alan Cuthbertson, Andreas Meijer, Bente E. Arbo, Magne Solbakken
  • Publication number: 20080305049
    Abstract: The invention relates to bifunctional conjugates comprising a receptor ligand moiety and a metal binding moiety and complexes thereof with paramagnetic lanthanide or transition metals, and to the use of the metal complexes as contrast agents in magnetic resonance imaging (MRI) of tumors and other abnormalities.
    Type: Application
    Filed: January 31, 2006
    Publication date: December 11, 2008
    Inventors: Hadassa Degani, David Stein
  • Publication number: 20080253969
    Abstract: Various biodegradable polyglutamate polymer conjugates that can include recurring units of the general formulae (I) and (II) are described herein. Such polymer conjugates are useful for variety of drug, targeting, stabilizing and/or imaging agent delivery applications.
    Type: Application
    Filed: April 8, 2008
    Publication date: October 16, 2008
    Applicant: NITTO DENKO CORPORATION
    Inventors: Lei Yu, Gang Zhao, Sang Van
  • Patent number: 7419654
    Abstract: A contrast agent for magnetic resonance imaging comprising a complex of a paramagnetic cation, preferably Gd+3, Dy+3, and Fe+3 with three equivalents of a charge neutralizing chelator that provides a lipid soluble complex of the paramagnetic cation is described. The complex is retained intracellularly when introduced into a mammalian cell. A method of providing an image of an internal pathology of a patient by magnetic resonance imaging (MRI) by administering the MRI contrast agent or tagged cells to the patient and scanning the patient using magnetic resonance imaging to obtain visible images of the internal pathology of the patient is also set forth.
    Type: Grant
    Filed: October 4, 2005
    Date of Patent: September 2, 2008
    Inventor: Mrinal K. Dewanjee
  • Publication number: 20080138292
    Abstract: The present invention generally relates to agents and compositions having MRI and/or optical signals, and methods for their use in the determination of an analyte. In some cases, an optical, MRI, or other signal produced by the agent or composition may be affected by the presence of an analyte. Some embodiments of the present invention may provide agents or compositions which are cell permeable. Examples of analytes that may be determined by the present invention include zinc ions, calcium ions, and other biological analytes.
    Type: Application
    Filed: September 14, 2007
    Publication date: June 12, 2008
    Applicant: Massachusetts Institute of Technology
    Inventors: Xiao-An Zhang, Alan Pradip Jasanoff, Stephen J. Lippard
  • Patent number: 7354568
    Abstract: The invention relates to novel magnetic resonance imaging contrast agents and methods of detecting physiological signals or substances.
    Type: Grant
    Filed: September 27, 1999
    Date of Patent: April 8, 2008
    Assignee: California Institute of Technology
    Inventors: Thomas Meade, Scott Fraser, Russell Jacobs
  • Patent number: 7344704
    Abstract: The invention relates to the use of perfluoroalkyl-containing metal complexes that have a critical micelle formation concentration <10?3 mol/l, a hydrodynamic micelle diameter (2 Rh)>1 nm and a proton relaxivity in plasma (R1)>10 l/mmol·s as contrast media in MR imaging for visualization of intravascular thrombi.
    Type: Grant
    Filed: July 10, 2003
    Date of Patent: March 18, 2008
    Assignee: Schering AG
    Inventors: Bernd Misselwitz, Johannes Platzek, Yoko Kawata, Hanns-Joachim Weinmann, Takashi Yokawa, Ulrich Niedballa